Expert Interviews

The leukemia expert offered an overview of agents approved by the FDA this year.

The Emory University Winship Cancer Institute expert discussed FDA approvals and other treatment advances that occurred this year.

The expert in urologic oncology spoke about the advancements made in 2020, as well as areas of prostate cancer care which he believes remain to be improved.

Payne and colleagues indicated that a significant number of adolescent and young adult women are still not being given the information they desire regarding fertility preservation and therefore are not making fully informed treatment decisions.

The American Lung Association’s annual “State of Lung Cancer” (SOLC) report tracked the toll of lung cancer at national and state levels, identifying both promising improvements for the overall population and significant health disparities for racial and ethnic minorities.

The founder and CEO of Sema4 spoke about what health care providers currently lack in preventing and treating diseases and what the reality of early detection and disease prevention can provide to patients with cancer.

The expert from Cedars-Sinai Cancer spoke about the continued integration of immunotherapy-based combination regimens, and the importance of utilizing the multidisciplinary care team to mitigate any possible toxicities that may arise.

Given that smoking is one of the major risk factors for recurrence of any cancer, Tsao explained that it's crucial that providers focus on smoking cessation in patients with cancer.

Given that diagnosing lung cancer in its early stages can lead to successfully eliminating lung cancer with surgery alone, the importance of closing this disparity gap is critical.

The SU2C–LUNGevity Foundation–American Lung Association Lung Cancer Interception Dream Team have developed laboratory models to understand the inflammatory process in the lung’s bronchial cells, and how that relates to early lung cancer development.

Ahlstrom explained the necessity of offering patients with cancer telehealth opportunities and what patients with cancer will lose should telehealth waivers expire.

Research published by Galvin, et al. in the journal ONCOLOGY® demonstrated the necessity to understand why eligible patients with pancreatic adenocarcinoma elect not to participate in early-phase clinical trials.

The Cancer Experience Registry was developed by the Cancer Support Community in order to collect information about the emotional and social effects of living with a cancer diagnosis.

Jeffrey Schneider, MD, and Marc Braunstein, MD, PhD, spoke about their recent article published in the journal ONCOLOGY® regarding the management of patients with cancer during the COVID-19 pandemic.

The leukemia expert spoke about the importance of genetic testing for patients with acute myeloid leukemia and other important considerations for this patient population throughout the pandemic.

The breast cancer expert discussed the changes he has made in treating this patient population as a result of the COVID-19 pandemic.

Moss indicated that “we need interventions in these communities to change cancer-causing behaviors, to make cancer screening more accessible, to improve treatment, and to promote quality of life and survivorship.”

The expert from the Otto J. Ruesch Center for the Cure of Gastrointestinal Cancers discussed precision medicine with regard to cancer care, as well as the need to make such care more accessible for the global community.

The findings from this study are intended to inform the Curriculum for Oncologists on LGBTQ+ populations to Optimize Relevance and Skills (COLORS) Training Program.

According to researchers, a “better understanding of the heterogeneity of mCRC, including primary tumor location, microsatellite instability (MSI) status, and other clinically actionable tumor mutations, is reshaping the therapeutic landscape.”

According to researchers, these early data support the rationale for further evaluation of immune-checkpoint inhibitor-based combinations in patients with metastatic castration resistant prostate cancer.

New guidelines published by the American Society for Clinical Oncology (ASCO) on the use of PARP inhibitors in the management of ovarian cancer included the myChoice CDx as the sole companion diagnostic to be used in this space.

The medical oncologist spoke about the need to make next-generation sequencing available to all patients with gastrointestinal cancer.

Germline analysis in patients with advanced cancer may play an important role in selecting FDA-approved treatments and clinical trial participation with germline-targeted therapeutics.

Roy S. Herbst, MD, PhD, of the Yale Cancer Center discussed his key takeaway from the phase III ADAURA trial regarding osimertinib as adjuvant therapy to treat NSCLC presented at the 2020 ASCO Virtual Scientific Program.